Skip to main content
SpringerLink
Log in

Procalcitonin and acute coronary syndromes: a new biomarker for an old disease

  • IM - Commentary
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341:515–518

    Article  PubMed  CAS  Google Scholar 

  2. Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker U, Jäger L, Reinhart K (1999) Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 134:49–55

    Article  PubMed  CAS  Google Scholar 

  3. Dandona P, Nix D, Wilson MF et al (1994) Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79:1605–1608

    Article  PubMed  CAS  Google Scholar 

  4. Rau B, Steinbach G, Gansauge F et al (1997) The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut 41:832–840

    Article  PubMed  CAS  Google Scholar 

  5. Muller B, Becker KL, Schochinger H, Rickenbacher PR, Huber PR, Zimmerli W et al (2000) Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 28:977–983

    Article  PubMed  CAS  Google Scholar 

  6. Ugarte H, Silva E, Mercan D, De Mendonca A, Vincent JL (1999) Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 27:498–504

    Article  PubMed  CAS  Google Scholar 

  7. Picariello C, Lazzeri C, Chiostri M, Gensini GF et al (2009) Procalcitonin in patients with acute coronary syndromes and cardiogenic shock submitted to percutaneous coronary intervention. Intern Emerg Med. doi:10.1007/s11739-009-0277-9

  8. Kafkas N, Venetsanou K, Patsilinakos S et al (2008) Procalcitonin in acute myocardial infarction. Acute Card Care 10:30–36

    Article  PubMed  Google Scholar 

  9. Senturk T, Cordan J, Baran I et al (2007) Procalcitonin in patients with acute coronary syndrome: correlation with high-sensitive C-reactive protein, prognosis and severity of coronary artery disease. Acta Cardiol 62:135–141

    Article  PubMed  Google Scholar 

  10. Buratti T, Ricevuti G, Pechlaner C et al (2001) Plasma levels of procalcitonin and interleukin-6 in acute myocardial infarction. Inflammation 25:97–100

    Article  PubMed  CAS  Google Scholar 

  11. Remskar M, Horvat M, Hojjer S et al (2002) Procalcitonin in patients with acute myocardial infarction. Wien Klin Wochenschr 114:205–210

    PubMed  CAS  Google Scholar 

  12. Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126

    Article  PubMed  CAS  Google Scholar 

  13. Liuzzo G, Biasucci LM, Gallimore JR et al (1994) The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331:417–424

    Article  PubMed  CAS  Google Scholar 

  14. Lindhal B, Toss H, Siegbahn A et al (2000) Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 343:1139–1147

    Article  Google Scholar 

  15. Brunkhorst FM, Clark AL, Forycki ZF, Anker SD (1999) Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. Int J Cardiol 72:3–10

    Article  PubMed  CAS  Google Scholar 

  16. Jensen JU, Lundgren B, Hein L, Mohr T, Petersen PL, Andersen LH, Lauritsen AO, Hougaard S, Mantoni T, Bømler B, Thornberg KJ, Thormar K, Løken J, Steensen M, Carl P, Petersen JA, Tousi H, Søe-Jensen P, Bestle M, Hestad S, Andersen MH, Fjeldborg P, Larsen KM, Rossau C, Thomsen CB, Ostergaard C, Kjaer J, Grarup J, Lundgren JD (2008) The Procalcitonin And Survival Study (PASS)—a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker procalcitonin and pro-active diagnostic and therapeutic responses to abnormal procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. BMC Infect Dis 8:91

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

L. M. Biasucci holds a research grant from Sanofi-Aventis and received consulting fees from Sanofi-Aventis, Roche Siemens diagnostic. All other authors have no conflict of interest to declare.

Author information

Authors and Affiliations

  1. Institute of Cardiology, Catholic University, Largo Gemelli 8, 00168, Rome, Italy

    Luigi M. Biasucci, Gina Biasillo & Antonella Stefanelli

Authors
  1. Luigi M. Biasucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gina Biasillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonella Stefanelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luigi M. Biasucci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Biasucci, L.M., Biasillo, G. & Stefanelli, A. Procalcitonin and acute coronary syndromes: a new biomarker for an old disease. Intern Emerg Med 4, 363–365 (2009). https://doi.org/10.1007/s11739-009-0295-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-009-0295-7

Search

Navigation